LoQus23 Therapeutics announces £35 million Series A financing to advance its small molecule somatic expansion inhibition therapy for Huntington's disease

LoQus23 Therapeutics England United States of America United Kingdom

Financing led by leading life sciences venture capital firm Forbion, with participation from existing investors SV Health Investors' Dementia Discovery Fund (DDF) and Novartis Venture Fund (NVF) Lead programme targeting MutS? set to enter the clinic in 2026, offering a potentially disease-modifying therapy for Huntington's diseaseForbion General Partner Rogier Rooswinkel joins Board of DirectorsView original content:https://www.prnewswire.co.uk/news-releases/loqus23-therapeutics-announces-35-million-c43-million-series-a-financing-to-advance-its-small-molecule-somatic-expansion-inhibition-therapy-for-huntingtons-disease-302264557.html